合計 50 件の最近のインサイダー取引記録が記録されています Femasys Inc. (FEMY), 内訳は 40 件の買い および 1 件の売り. インサイダー買い総額は $1.52M インサイダー売り総額は $6.25M.
最近活動のある主要インサイダーには Canning John Charles, Elefant Dov, Lee-sepsick Kathy. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — FEMY
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2026-03-30 |
Canning John Charles |
Chief Operating Officer |
不明 |
- |
- |
- |
30,000 |
| 2026-03-30 |
Canning John Charles |
Chief Operating Officer |
RSU 付与（制限付株式） |
150,000 |
$0.38 |
$57K |
150,000 |
| 2026-03-19 |
Elefant Dov |
Chief Financial Officer |
RSU 付与（制限付株式） |
34,122 |
$0.58 |
$19.79K |
34,122 |
| 2026-03-19 |
Lee-sepsick Kathy |
Chief Executive Officer |
RSU 付与（制限付株式） |
68,244 |
$0.58 |
$39.58K |
68,244 |
| 2026-03-19 |
Larsen Charles |
Director |
RSU 付与（制限付株式） |
34,122 |
$0.58 |
$19.79K |
34,122 |
| 2026-03-19 |
Eichenbaum Kenneth D. |
Director |
RSU 付与（制限付株式） |
102,366 |
$0.58 |
$59.37K |
102,366 |
| 2026-03-18 |
Eichenbaum Kenneth D. |
Director |
RSU 付与（制限付株式） |
35,200 |
$0.60 |
$21.12K |
35,200 |
| 2026-03-18 |
Eichenbaum Kenneth D. |
Director |
不明 |
- |
- |
- |
25,010 |
| 2026-03-17 |
Pharmacyte Biotech, Inc. |
10 Percent Owner |
不明 |
- |
- |
- |
- |
| 2026-03-17 |
Silverman Joshua |
Director |
不明 |
- |
- |
- |
- |
| 2026-02-19 |
Elefant Dov |
Chief Financial Officer |
RSU 付与（制限付株式） |
169,000 |
- |
- |
169,000 |
| 2026-02-19 |
Lee-sepsick Kathy |
Chief Executive Officer |
RSU 付与（制限付株式） |
282,000 |
- |
- |
282,000 |
| 2026-02-02 |
Sipos Jeremy Alexander |
Chief Technology Officer |
RSU 付与（制限付株式） |
80,000 |
- |
- |
80,000 |
| 2025-12-16 |
Sipos Jeremy Alexander |
Chief Technology Officer |
不明 |
3,334 |
$6.12 |
$20.4K |
- |
| 2025-11-07 |
Elefant Dov |
Chief Financial Officer |
裁量買い |
- |
$0.73 |
- |
- |
| 2025-11-07 |
Larsen Charles |
Director |
裁量買い |
- |
$0.73 |
- |
- |
| 2025-11-07 |
Lee-sepsick Kathy |
Chief Executive Officer |
裁量買い |
- |
$0.73 |
- |
- |
| 2025-11-07 |
Eichenbaum Kenneth D. |
Director |
不明 |
102,366 |
$1.10 |
$112.6K |
- |
| 2025-08-27 |
Elefant Dov |
Chief Financial Officer |
裁量買い |
38,828 |
$0.52 |
$20K |
38,828 |
| 2025-08-27 |
Lee-sepsick Kathy |
Chief Executive Officer |
裁量買い |
48,535 |
$0.52 |
$25K |
48,535 |
| 2025-06-25 |
Silverman Joshua |
Director |
RSU 付与（制限付株式） |
17,600 |
$0.98 |
$17.25K |
17,600 |
| 2025-06-25 |
Uzialko Edward R |
Director |
RSU 付与（制限付株式） |
17,600 |
$0.98 |
$17.25K |
17,600 |
| 2025-06-25 |
Larsen Charles |
Director |
RSU 付与（制限付株式） |
17,600 |
$0.98 |
$17.25K |
17,600 |
| 2025-06-25 |
Milnes Alistair |
Director |
RSU 付与（制限付株式） |
17,600 |
$0.98 |
$17.25K |
17,600 |
| 2025-06-23 |
Nicholas Kelley Stinson |
Chief Commercial Officer |
不明 |
- |
- |
- |
45 |
| 2025-06-23 |
Nicholas Kelley Stinson |
Chief Commercial Officer |
RSU 付与（制限付株式） |
100,000 |
$0.90 |
$90K |
100,000 |
| 2025-06-02 |
Elefant Dov |
Chief Financial Officer |
裁量買い |
19,608 |
$1.02 |
$20K |
19,608 |
| 2025-06-02 |
Lee-sepsick Kathy |
Chief Executive Officer |
裁量買い |
34,314 |
$1.02 |
$35K |
312,092 |
| 2025-06-02 |
Currie Daniel Scott |
Chief Operating Officer |
裁量買い |
19,608 |
$1.02 |
$20K |
86,275 |
| 2025-06-02 |
Larsen Charles |
Director |
裁量買い |
24,510 |
$1.02 |
$25K |
56 |
| 2025-01-29 |
Lee-sepsick Kathy |
Chief Executive Officer |
RSU 付与（制限付株式） |
59,849 |
$1.17 |
$70.02K |
59,849 |
| 2025-01-28 |
Elefant Dov |
Chief Financial Officer |
RSU 付与（制限付株式） |
72,045 |
$1.05 |
$75.65K |
72,045 |
| 2025-01-28 |
Currie Daniel Scott |
Chief Operating Officer |
RSU 付与（制限付株式） |
29,184 |
$1.05 |
$30.64K |
29,184 |
| 2025-01-28 |
Thomas Christine E |
Chief Reg & Clinical Officer |
RSU 付与（制限付株式） |
23,600 |
$1.05 |
$24.78K |
23,600 |
| 2024-07-12 |
Silverman Joshua |
Director |
RSU 付与（制限付株式） |
17,600 |
$1.14 |
$20.06K |
17,600 |
| 2024-07-12 |
Uzialko Edward R |
Director |
RSU 付与（制限付株式） |
17,600 |
$1.14 |
$20.06K |
17,600 |
| 2024-07-12 |
Larsen Charles |
Director |
RSU 付与（制限付株式） |
17,600 |
$1.14 |
$20.06K |
17,600 |
| 2024-07-12 |
Milnes Alistair |
Director |
RSU 付与（制限付株式） |
17,600 |
$1.14 |
$20.06K |
17,600 |
| 2024-02-12 |
Spector Richard D. |
Officer |
不明 |
- |
- |
- |
- |
| 2024-02-12 |
Spector Richard D. |
Chief Commercial Officer |
RSU 付与（制限付株式） |
100,000 |
$1.10 |
$110K |
100,000 |
| 2024-02-01 |
Elefant Dov |
Chief Financial Officer |
RSU 付与（制限付株式） |
84,000 |
$0.80 |
$67.2K |
84,000 |
| 2024-02-01 |
Lee-sepsick Kathy |
Chief Executive Officer |
RSU 付与（制限付株式） |
204,900 |
$0.80 |
$163.92K |
204,900 |
| 2024-02-01 |
Currie Daniel Scott |
Chief Operating Officer |
RSU 付与（制限付株式） |
61,900 |
$0.80 |
$49.52K |
61,900 |
| 2024-02-01 |
Thomas Christine E |
SVP, Regulatory & Clinical |
RSU 付与（制限付株式） |
32,600 |
$0.80 |
$26.08K |
32,600 |
| 2023-11-21 |
Silverman Joshua |
Officer |
不明 |
- |
- |
- |
- |
| 2023-11-21 |
Silverman Joshua |
Director |
RSU 付与（制限付株式） |
17,000 |
$0.90 |
$15.3K |
17,000 |
| 2023-11-21 |
Pharmacyte Biotech, Inc. |
10 Percent Owner |
処分 |
4,237,288 |
$1.48 |
$6.25M |
- |
| 2023-10-10 |
Thomas Christine E |
SVP, Regulatory & Clinical |
RSU 付与（制限付株式） |
60,000 |
$1.76 |
$105.6K |
60,000 |
| 2023-07-03 |
Elefant Dov |
Chief Financial Officer |
RSU 付与（制限付株式） |
105,200 |
$0.49 |
$51.55K |
105,200 |
| 2023-07-03 |
Lee-sepsick Kathy |
Chief Executive Officer |
RSU 付与（制限付株式） |
270,400 |
$0.49 |
$132.5K |
270,400 |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
